Resilience defines UK healthcare M&A in Q2 2026

Despite a challenging start to the year, recent data has emphasised the healthcare sector’s status as one of the UK’s most resilient M&A markets. Dealmaking in the sector during Q2 2026 was boosted by strong levels of activity in the Health and Social Care sub-sector, as well as high value deals in Pharmaceuticals and Life Sciences.

According to the latest Q2 UK Healthcare M&A Update from Heligan Group, there were 78 transactions announced and completed in the UK healthcare sector during Q2 2026, a 47 per cent increase from the 53 deals recorded during a slower start to the year in Q1.

This put the period roughly in line with Q2 2025, as domestic buyers continued to dominate activity. 69 per cent of activity consisted of internal UK transactions, compared to 22 per cent outbound activity, with overseas M&A described as primarily occurring only with a clear strategic rationale.

Approximately 86 per cent of deals completed during Q2 2026 involved strategic buyers, indicating continuing confidence in the sector, despite persistent macroeconomic uncertainty.

Ramesh Jassal, Partner, Healthcare at Heligan Group, commented: “While broader deal making remains challenging with geopolitical uncertainty and domestic political pressures, the healthcare sector continues to demonstrate resilience. Long-term demand drivers are still giving buyers clear reasons to invest, even where diligence is taking longer, and valuations are being tested.”

The Health and Social Care sub-sector continued to be the main driver of deal volume, accounting for 69 per cent of transactions during the quarter. The sub-sector spans residential elderly care, specialist care, childcare and nurseries (identified as one of the busiest specialist markets within the sector) and home care.

Ramesh Jassal said that Health and Social Care dealmaking reflected “the breadth of consolidation pressures across the care economy.”

He continued: “Nursery transactions accounted for 14% of deals across the quarter. The market remains fragmented, with many independent settings facing rising staffing costs, tighter regulatory demands and increasing administrative complexity around funded childcare hours.”

Jassal added that this creates a compelling consolidation prospect for larger operators, providing the opportunity to “acquire smaller nurseries, professionalise operations, improve utilisation and benefit from procurement, systems and management efficiencies” and ultimately build scale within a fragmented market.

While the bulk of activity was concentrated in the Health and Social Care market, the quarter’s highest-value deals were found in the Pharmaceuticals and Life Sciences sub-sector.

According to Heligan Group, a number of major deals, particularly GSK’s proposed £7.95 billion acquisition of Nuvalent, demonstrated the strong demand for differentiated, late-stage assets operating in the life sciences market.

Jassal stated: “The GSK acquisition underlines the company’s strategy of acquiring late-stage, differentiated oncology assets with near-term commercial potential. This reflects a continued appetite among major pharmaceutical companies for differentiated assets capable of strengthening long-term growth pipelines.”

Looking ahead, Jassal forecasts that strong underlying demand, ongoing interest from strategic buyers and wider demographic trends will continue to drive consolidation across the healthcare market.

He commented: “Healthcare remains one of the most resilient areas of the UK M&A market. We expect consolidation activity to continue across care services, healthcare technology, specialist providers and life sciences, while nursery M&A is also likely to remain active given the sector’s fragmented ownership structure and favourable long-term demand drivers.”

Find out more about what's driving the ongoing surge in Health and Social Care dealmaking

Share this article

Latest Businesses for Sale

---

---

---

View more businesses for sale